First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014. - Wikidata - wikimedia - TriplyDB

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

http://www.wikidata.org/entity/Q35881827

about

Novel drugs that target the metabolic reprogramming in renal cell cancer The mTOR pathway in obesity driven gastrointestinal cancers: Potential targets and clinical trials Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics PI3K/Akt/mTOR inhibitors in breast cancer Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1 Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.BEZ235 (PIK3/mTOR inhibitor) Overcomes Pazopanib Resistance in Patient-Derived Refractory Soft Tissue Sarcoma Cells A first in man, dose-finding study of the mTORC1/mTORC2 inhibitor OSI-027 in patients with advanced solid malignancies.Insights into significance of combined inhibition of MEK and m-TOR signalling output in KRAS mutant non-small-cell lung cancer Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways.Molecular regulation of apoptotic machinery and lipid metabolism by mTORC1/mTORC2 dual inhibitors in preclinical models of HER2+/PIK3CAmut breast cancer.The novel combination of dual mTOR inhibitor AZD2014 and pan-PIM inhibitor AZD1208 inhibits growth in acute myeloid leukemia via HSF pathway suppression.Platelet-derived growth factor (PDGF) signalling in cancer: rapidly emerging signalling landscape.Inhibiting 4EBP1 in glioblastoma.Targeting mTOR for the treatment of B cell malignancies.New perspectives on mTOR inhibitors (rapamycin, rapalogs and TORKinibs) in transplantation.Long-term acquired everolimus resistance in pancreatic neuroendocrine tumours can be overcome with novel PI3K-AKT-mTOR inhibitors.Autophagy: controlling cell fate in rheumatic diseases.Recent advances in targeting mTOR signaling pathway using small molecule inhibitors.mTORC1 and mTORC2 in cancer and the tumor microenvironment.PI3K/AKT/mTOR: role in breast cancer progression, drug resistance, and treatment.Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.mTORC2 Signaling Drives the Development and Progression of Pancreatic Cancer.JQ1 synergizes with the Bcl-2 inhibitor ABT-263 against MYCN-amplified small cell lung cancer.Uncoupling TORC2 from AGC kinases inhibits tumour growth.The PI3K Pathway in Human Disease.Influence of the Novel ATP-Competitive Dual mTORC1/2 Inhibitor AZD2014 on Immune Cell Populations and Heart Allograft Rejection.RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.A small molecule inhibitor of Rheb selectively targets mTORC1 signaling.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.mTOR inhibition enhances efficacy of dasatinib in ABL-rearranged Ph-like B-ALL.

P2860

Q26740187-EF76F8A6-B295-43BF-8BA0-28A933E923B1 Q26751155-7F34033B-310F-4335-8BA2-A7DB7A2E52B4 Q26766292-AA383838-6B2B-4244-86D8-CB97BDB8186B Q26771394-F38E4D47-FBF9-4C63-8F57-5B4977C5853D Q28071388-CDEE67A5-B8D0-496E-9F05-4A9894EF3C78 Q30396975-EAABC0C5-8FDF-47C5-B881-71153F65709C Q33798463-BDD3C7D5-C48E-4447-8B11-B91CF571458B Q36992455-AB26A246-D6FD-4E67-AE78-F2D9CA552FFF Q37004340-A640D5C6-E45F-4E1D-9DA2-010D947E8534 Q37174723-3D790D9C-8DA2-4654-9F0F-001638B8B986 Q37203121-090C42D7-C53B-4F38-8B8A-C5786B7A56CF Q37277855-8B48F090-C5AD-4AD8-BC10-A2702C0FEE02 Q37687122-9EABD4CD-69AF-4428-A0EF-A22A5502C3B4 Q38262117-E47A9C9F-CD21-430C-BF51-DD1D48467FDB Q38543837-90429C33-1B08-4826-B0B8-08748C250117 Q38659417-016FDD4A-13A7-4348-BCAD-C081D164CB76 Q38709825-FF7AFCEF-7EEF-475C-9CD4-EE6E0F2CF81A Q38711763-77102596-3D8D-4122-97DC-EEEA4A3F416E Q38786234-AA2F64DF-C267-4DE3-B8D6-EC5ADED8A1D9 Q38873681-13A56392-0060-48F1-B8F3-018443605ADD Q38955246-F46F5B6F-EEC8-4004-BBE6-48907EEADD9A Q38982579-A4096B7E-1206-42A6-B565-21DE8DF668F0 Q39023175-AEE3CDE5-A130-4B88-AE6A-80625231CFAC Q41195708-29471EFB-95A4-4275-8470-C7BEB3A700A3 Q42359443-8B35E989-8869-4ECA-9281-1B028D8070C7 Q44268034-12994525-3CCB-4675-94D8-7E0225E5CD8E Q46156033-1C5FB820-CEFF-402A-A8AD-7EAF125E3EA3 Q46546002-3B27208D-1B29-4D2C-8027-01F902D07F64 Q47835201-9D874D4D-BAF0-456B-B5A9-6C3BCA5E203A Q48123819-CB42A978-DF2E-4646-B086-BC29F2F71C0D Q49198717-C7803AB7-B872-4325-9F28-A63B758FBF5C Q49393542-E62B766D-5BE1-4A5C-AC55-4368C7E4D1D7 Q49787386-770F6086-5CDE-4865-AE8B-8F14182A6AAC

P2860

First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014.

http://www.wikidata.org/entity/Q35881827

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.

@ast

First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.

@en

type

label

First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.

@ast

First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.

@en

prefLabel

First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.

@ast

First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.

@en

P1433

Q35881827-3859B15F-508B-4266-AACA-22BD9B939412

P1476

Q35881827-2FCB6CCA-AC2F-41DA-BB8F-5B44D164F36F

P2093

Q35881827-0CF7F25E-8E75-4E44-81AC-96D0341C14DE

Q35881827-230D1C41-1F5B-4D55-B0D3-BBA030D26577

Q35881827-60AD9ACE-344A-4F0C-880B-C47DDB54E654

Q35881827-79137A85-F7A0-4E4C-A441-517D66DB612B

Q35881827-888032A6-CF72-48B7-AFFA-05810BC1F719

Q35881827-8EF0723F-FE75-41FF-8F5C-223D9ED682AD

Q35881827-A012CB82-3F4F-400C-B1FC-5D160920A540

Q35881827-A4271EB3-DB9F-4C0E-A9E2-98D56E2F3F69

Q35881827-BA598328-BBE6-4539-8FCA-A9D892E755A7

Q35881827-D00F4BD5-5E46-4DD8-B31F-D92F0E55DEC9

P2860

Q35881827-002F34A4-7AF0-4272-BDDE-03EB9579BC97

Q35881827-01426AC8-F207-46DA-8DC9-6593B509E12B

Q35881827-18A4C35C-FD72-4875-80DE-4C04D4DDADAB

Q35881827-1B3D40AE-4929-413B-ADFC-E418C1DDB420

Q35881827-222E69CA-9809-40DD-963E-FFF7E50BBB64

Q35881827-2D6A3015-1FB9-45A4-AC6D-4039326155B3

Q35881827-3FED71D9-7F88-4B18-BC47-D3063756B21C

Q35881827-5020EBA4-6841-42CE-BAD6-02134A7B8501

Q35881827-586EC5AD-D264-4E3D-AEB1-134FB54DA12C

Q35881827-7D34917C-A06D-4389-9533-C05A6F2D2CD2

P304

Q35881827-1A5B56BE-C009-420B-A49A-66D5ECD53707

P31

Q35881827-54B7D32D-7B58-4F4E-8508-6267A9B2D967

P356

Q35881827-66E076D2-C837-4065-ADFF-CB16A2292EB6

P407

Q35881827-344160D6-09DD-4528-AF9F-A5A3C5499F4A

P433

Q35881827-F75DF80C-CB05-4130-88B7-47438EAE4727

P478

Q35881827-626C1152-2583-4F33-9E1B-B45BE4234CA4

P50

Q35881827-B0116B3D-C080-494F-A6BB-EAAAAECCA10B

Q35881827-BF042A02-FE75-4357-9E8B-4601CD5A8595

Q35881827-D198F905-CD3D-435A-A5F9-EDEB01BB431D

Q35881827-F47E4349-4100-44B7-9FE6-213F0884F573

P577

Q35881827-A2642098-E579-4D25-8167-D3FB33A4EE71

P698

Q35881827-6A35068A-E729-420A-BA4B-D97C91A1E05B

P932

Q35881827-16F6C45D-98FC-4E12-ADE1-9F6FAA645386

P356

1078-0432.CCR-14-2422

P1433

Clinical Cancer Research

P1476

First-in-Human Pharmacokinetic ...... m-TORC 1/2 Inhibitor AZD2014.

@en

P2093

Bristi Basu

http://www.w3.org/2001/XMLSchema#string

Christopher Womack

http://www.w3.org/2001/XMLSchema#string

Elisabeth Oelmann

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Harrington

http://www.w3.org/2001/XMLSchema#string

Graham Bigley

http://www.w3.org/2001/XMLSchema#string

Johann S de Bono

http://www.w3.org/2001/XMLSchema#string

Malcolm Ranson

http://www.w3.org/2001/XMLSchema#string

Maria Cavallin

http://www.w3.org/2001/XMLSchema#string

Martina Puglisi

http://www.w3.org/2001/XMLSchema#string

Stephen Green

http://www.w3.org/2001/XMLSchema#string

P2860

Defining the role of mTOR in cancer

Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

Targeting the phosphoinositide 3-kinase pathway in cancer

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

mTOR signaling at a glance

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

P304

3412-3419

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-14-2422

http://www.w3.org/2001/XMLSchema#string

P407

P433

15

http://www.w3.org/2001/XMLSchema#string

P478

21

http://www.w3.org/2001/XMLSchema#string

P50

Alastair Peter Greystoke

P577

2015-03-24T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25805799

http://www.w3.org/2001/XMLSchema#string

P932

4512239

http://www.w3.org/2001/XMLSchema#string